A phase 1/2 study of SKI-606, a dual inhibitor of src and abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib.

被引：18

作者：

Cortes, Jorge

Kantarjian, Hagop M.

Baccarani, Michele

Brummendorf, Tim H.

Liu, Delong

Ossenkoppele, Gert

Volkert, Angela D. G.

Hewes, Becker

Moore, Laurence

Zacharchuk, Charles

Gambacorti, Carlo

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Studi Bologna, Bologna, Italy

[3] Univ Hamburg Hosp, Med Klin & Poliklin, D-2000 Hamburg, Germany

[4] New York Med Coll, Valhalla, NY 10595 USA

[5] VU Univ Med Ctr, Amsterdam, Netherlands

[6] Wyeth Ayerst Res, CR&D, Cambridge, MA USA

[7] Univ Milan, San Gerardo Hosp, Monza, Italy

来源：

关键词：

D O I：

10.1182/blood.V108.11.168.168

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

168

引用

页码：54A / 54A

页数：1